Search Bar & Filters
Found 26 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Respiratory syncytial virus RSV is a common virus affecting children, especially young babies, premature infants, and those with heart or lung problems. It is a leading cause of hospitalization for children under 5 years old globally, with many severe cases and deaths occurring in low- and middle-income countries. This research evaluates the safety of an RSV vaccine called ABRYSVO given to pregnant women and how well it protects their infants from severe RSV infections during the first six months of life, particularly in African and lower-middle income countries where data is limited. Pregnant women will receive either the ABRYSVO vaccine or a placebo in a randomized, double-blind trial. The vaccine contains stabilized RSV prefusion F antigens from virus subgroups A and B. The study will enroll pregnant women at the approved gestational age for vaccination, with participants randomly assigned to receive either the vaccine or placebo in equal numbers. The trial will monitor the safety of the vaccine in mothers and infants and measure how well the vaccine prevents severe RSV lower respiratory tract infections in babies up to 180 days old. Participants will attend antenatal clinics and provide informed consent for themselves and their infants. Researchers will follow the women through pregnancy and delivery, recording any preterm births and birth weights. Infants will be monitored for RSV infections confirmed by laboratory tests, and hospitalizations due to RSV will be tracked up to six months of age. Safety assessments include monitoring adverse events in mothers and babies, with follow-up visits and telephone contacts to ensure comprehensive data collection throughout the trial period.
Actively Recruiting
Researchers are evaluating etavopivat, a new oral medicine being developed for blood disorders such as sickle cell disease and thalassaemia. These inherited conditions affect hemoglobin, the protein responsible for carrying oxygen in the body. This long-term study aims to assess the safety and effectiveness of etavopivat treatment over a period of up to 264 weeks, or until the drug is approved in the participants country. Participants will receive one of several oral doses of etavopivat, with dosing adjusted by age those 12 years and older will receive Etavopivat A or C, while children younger than 12 years will receive Etavopivat B. The study involves multiple groups including adults, adolescents, and children with different types of sickle cell disease or thalassaemia. All participants have completed a prior etavopivat treatment study and are continuing treatment in this rollover study. During the study, participants will be regularly monitored for treatment-related side effects and clinical benefits. Researchers will track adverse events, blood crisis rates, hemoglobin levels, hospitalizations, and blood transfusion needs. The study includes long-term safety and efficacy assessments conducted over several years, with monitoring continuing until study completion or drug approval. Participants health and treatment responses will be carefully followed throughout this extended period.
Actively Recruiting
Healthy Volunteer
Researchers are investigating new medicines to prevent Human Immunodeficiency Virus Type 1 HIV-1 infection, focusing on women aged 16 to 30 years who are at risk. The study aims to compare the effectiveness and safety of taking MK-8527 once a month against a standard daily pre-exposure prophylaxis PrEP regimen. This phase 3 trial is designed to evaluate if MK-8527 can better prevent HIV-1 infection and how well participants tolerate this medication. Participants will be randomly assigned to one of two groups. One group will take 11 mg of MK-8527 once monthly and a daily placebo matching the standard PrEP medication. The other group will take the daily standard PrEP drugs Emtricitabinetenofovir disoproxil FTCTDF and a monthly placebo matching MK-8527, both for up to approximately two years. After this period, all participants will receive open-label FTCTDF daily for an additional 28 days. During the study, participants will undergo regular monitoring to track new HIV-1 infections, any adverse events, and reasons for discontinuing the study drug due to side effects. The safety and tolerability of MK-8527 will be assessed over the approximately two-year treatment period. The research team will collect data on these outcomes to understand the benefits and risks of MK-8527 as a preventive option for HIV-1 infection.
Actively Recruiting
Researchers are studying pediatric cryptosporidiosis to better understand how this infection presents and progresses in children aged 6 to 59 months. The focus is on characterizing the clinical features and course of diarrhea caused by Cryptosporidium, a parasite common in certain regions. This observational study aims to gather detailed information on symptoms and outcomes in affected children. Participants are children with diarrhea due to Cryptosporidium infection confirmed by specific stool tests. The study observes children with varying durations of diarrheafrom acute to chronicand different nutritional statuses. The study follows children for up to 21 days, monitoring diarrhea severity, dehydration, and parasite presence without administering any treatment. During participation, children will be assessed at multiple time points including baseline, days 3, 7, 14, and up to day 21. Researchers will collect stool samples and evaluate dehydration severity, diarrhea resolution time, and parasite shedding. Additional factors like age, nutritional status, and breastfeeding history will be analyzed to understand their association with illness duration and severity. Participants will be followed closely to capture the natural course of infection and symptoms.
Actively Recruiting
Researchers are evaluating etavopivat in adolescents and adults with sickle cell disease to see if it can reduce vaso-occlusive crises painful blockages in blood vessels and protect organs from damage. This phase 3 study will also assess whether etavopivat improves exercise tolerance and reduces fatigue compared to a placebo. The trial is randomized, double-blind, and placebo-controlled to ensure unbiased results on the medications effects. Participants will be randomly assigned to receive either oral etavopivat or a matching placebo. The study treatment is taken by mouth, and participants will be followed closely for about 2 years. This includes monitoring during the treatment period and ongoing assessments to evaluate the drugs impact on sickle cell disease symptoms and related health measures. Throughout the study, participants will undergo evaluations such as blood tests to measure hemoglobin and other markers, 6-minute walking tests to assess exercise capacity, and fatigue questionnaires. Researchers will track the number of vaso-occlusive crises requiring medical contact over 52 weeks as the primary outcome. Safety and efficacy will be monitored regularly, with follow-up continuing until the study ends approximately 4 years after enrollment begins.
Actively Recruiting
Researchers are evaluating the pharmacokinetics and safety of etavopivat in children with sickle cell disease SCD. The study involves pediatric participants ranging in age from 6 months to less than 18 years and is designed as a phase 2, open-label, single-group study. Participants will be enrolled in age-based cohorts starting with the oldest group, with younger groups added sequentially after reviewing safety and pharmacokinetic data from prior cohorts. Participants will receive oral etavopivat once daily as either tablets or granules. The treatment includes a primary period lasting 24 weeks, followed by a 72-week extension period to further assess long-term safety and pharmacokinetics. The total study duration for each participant is approximately 96 weeks. Four age cohorts are studied 12 to less than 18 years, 6 to less than 12 years, 2 to less than 6 years, and 6 months to less than 2 years. Throughout the study, participants will be closely monitored with blood tests measuring etavopivat levels and hemoglobin changes, assessments of vaso-occlusive crisis frequency, and fatigue scales. Safety is evaluated by tracking adverse events, dose changes, and treatment interruptions. Transcranial Doppler ultrasound is used to assess cerebral blood flow at scheduled visits. The study includes frequent evaluations during both treatment periods to understand the drugs effects and safety in this young population.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of crizanlizumab, a biological drug given at 5 mgkg, compared to a placebo in adolescents and adults aged 12 years and older who have Sickle Cell Disease and experience frequent vaso-occlusive crises VOCs. This phase III, multicenter, randomized, double-blind study includes patients who may or may not be receiving hydroxyurea or hydroxycarbamide therapy. The study aims to better understand how crizanlizumab impacts the rate and severity of VOCs in this population. Participants will be randomly assigned in a 21 ratio to receive either crizanlizumab or placebo, with both groups continuing standard care. The treatment is given as an intravenous infusion and the study allows patients to continue stable doses of hydroxyurea or hydroxycarbamide if they are already on these therapies. The randomization is stratified by hydroxyureahydroxycarbamide use and geographic region. The study treatment period lasts for one year, during which participants receive regular infusions and monitoring. During the trial, participants will be closely monitored with healthcare assessments to track the number of healthcare professional-managed VOCs, time to first VOC, and other important measures such as duration of VOCs, antibody development to the study drug, and changes in hemoglobin levels. Safety is closely evaluated through recording of adverse events over a two-year period. Participants will have regular visits for treatment and evaluation throughout the study, which is expected to last up to six years including follow-up and completion phases.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the Shamba Maisha intervention to reduce HIV and sexually transmitted infections STIs among adolescent girls and young women AGYW aged 15 to 19 years in Kisumu and Migori counties, Kenya. This study addresses the high rates of HIVSTIs and food insecurity in this region by testing a sustainable, multi-level agricultural and economic approach. The goal is to improve sexual and reproductive health outcomes by targeting household food insecurity and strengthening adolescent-caregiver relationships. The Shamba Maisha intervention includes three main components providing families with water pumps, seeds, and farming tools along with training on their use engaging AGYW in practical farming activities at school demonstration farms and conducting sessions to strengthen communication and reduce stress between caregivers and adolescents, including discussions on sexual health. The study will randomize 20 schools to either receive this intervention or serve as controls, following 800 AGYW-caregiver pairs for 18 months. Participants will undergo surveys, STI and pregnancy testing at baseline and at 6, 12, and 18 months to assess outcomes such as STI incidence, household food insecurity, adolescent and caregiver mental health, and parent-child communication. Secondary measures include BMI, anxiety, condom use, intimate partner violence, empowerment, and educational attainment. The study will also identify factors influencing implementation and assess program costs to inform the potential for broader application of this intervention.
Actively Recruiting
Healthy Volunteer
Neonatal mortality, defined as death within the first 28 days of life, remains very high in sub-Saharan Africa, including Kenya where about 40,000 neonatal deaths occur yearly. This trial evaluates a two-way interactive SMS messaging program, called CHV-NEO, designed to improve communication between mothers and community health volunteers CHVs during the critical early weeks after birth. The study is a cluster-randomized control trial conducted in Western Kenya to assess whether this digital support can reduce neonatal deaths and improve newborn care. CHV-NEO integrates with an existing digital community health toolkit dCHT used by CHVs to manage their workflow and client visits. Mothers in the intervention group receive daily automated messages that guide them in recognizing danger signs in their newborns and allow real-time text communication with CHVs between monthly home visits. The control group continues with standard care, meaning CHVs provide usual monthly visits without the SMS support. This trial includes 20 facility clusters randomly assigned to either control or intervention. Participants will be pregnant women 26-36 weeks gestation who have daily mobile phone access and can read or have help reading messages in English, Kiswahili, or Luo. Researchers will track neonatal mortality up to 28 days after birth and assess newborn care practices like cord care, thermal care, breastfeeding initiation, and care-seeking behavior. Maternal knowledge of neonatal danger signs will also be measured. The study involves follow-up up to 6 weeks postpartum to monitor outcomes and acceptability of the SMS intervention.
Actively Recruiting
Healthy Volunteer
Researchers are studying the introduction of HIV testing services HTS counselor-led Pre-exposure Prophylaxis PrEP care in public family planning clinics in Kenya. This cluster randomized, stepped wedge study evaluates how delivering PrEP through HTS counselors affects HIV prevention efforts in these clinics. The study aims to improve integration of PrEP services into existing healthcare settings to support prevention of HIV infection. The study compares two periods a control period where clinics continue usual care with no counselor-led PrEP delivery, and an intervention period where HTS counselors provide all core PrEP services including HIV testing, eligibility assessment, medication dispensing, adherence counseling, and refills. A baseline phase of 3 months precedes the intervention to establish usual care standards. The intervention is delivered as part of the standard care by existing clinic staff. Participants are individuals aged 15 years and older accessing services at participating public health facilities who are not known to be living with HIV at study start. Researchers will monitor PrEP screening, initiation, and continuation over up to 42 months. Data collection includes tracking delivery of PrEP care by HTS counselors and participant adherence. The study runs from December 2025 through June 2029, with primary outcome data expected by December 2028.
1-10 of 26
1